%0 Journal Article %1 hill2021metaanalysis %A Hill, Andrew %A Garratt, Anna %A Levi, Jacob %A Falconer, Jonathan %A Ellis, Leah Kaitlyn %A McCann, Kaitlyn %A Pilkington, Victoria %A Qavi, Ambar %A Wang, Junzheng %A Wentzel, Hannah %D 2021 %J Oxford Academia %K SARs-CoV-2 covid ivermectin %R https://doi.org/10.1093/ofid/ofab358 %T Meta-analysis of randomized trial of Ivermectin to treat SARs-CoV-2 infection %U https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab358/6316214 %X Ivermectin is an antiparasitic drug being investigated for repurposing against SARS-CoV-2. Ivermectin showed in-vitro activity against SARS-COV-2 at high concentrations. This meta-analysis investigated ivermectin in 24 randomized clinical trials (3328 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv and trial registries. Ivermectin was associated with reduced inflammatory markers (C-Reactive Protein, d-dimer and ferritin) and faster viral clearance by PCR. Viral clearance was treatment dose- and duration-dependent. In 11 randomized trials of moderate/severe infection, there was a 56% reduction in mortality (Relative Risk 0.44 95%CI 0.25-0.77; p=0.004; 35/1064 (3%) deaths on ivermectin; 93/1063 (9%) deaths in controls) with favorable clinical recovery and reduced hospitalization. Many studies included were not peer reviewed and a wide range of doses were evaluated. Currently, WHO recommends the use of ivermectin only inside clinical trials. A network of large clinical trials is in progress to validate the results seen to date.

@article{hill2021metaanalysis, abstract = {Ivermectin is an antiparasitic drug being investigated for repurposing against SARS-CoV-2. Ivermectin showed in-vitro activity against SARS-COV-2 at high concentrations. This meta-analysis investigated ivermectin in 24 randomized clinical trials (3328 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv and trial registries. Ivermectin was associated with reduced inflammatory markers (C-Reactive Protein, d-dimer and ferritin) and faster viral clearance by PCR. Viral clearance was treatment dose- and duration-dependent. In 11 randomized trials of moderate/severe infection, there was a 56% reduction in mortality (Relative Risk 0.44 [95%CI 0.25-0.77]; p=0.004; 35/1064 (3%) deaths on ivermectin; 93/1063 (9%) deaths in controls) with favorable clinical recovery and reduced hospitalization. Many studies included were not peer reviewed and a wide range of doses were evaluated. Currently, WHO recommends the use of ivermectin only inside clinical trials. A network of large clinical trials is in progress to validate the results seen to date.}, added-at = {2021-07-11T16:26:59.000+0200}, author = {Hill, Andrew and Garratt, Anna and Levi, Jacob and Falconer, Jonathan and Ellis, Leah Kaitlyn and McCann, Kaitlyn and Pilkington, Victoria and Qavi, Ambar and Wang, Junzheng and Wentzel, Hannah}, biburl = {https://www.bibsonomy.org/bibtex/2489bd52ea5257722d2a091175c2c4dd2/bellao}, doi = {https://doi.org/10.1093/ofid/ofab358}, interhash = {25f980fe4ae2a224c2383f6057e625a9}, intrahash = {489bd52ea5257722d2a091175c2c4dd2}, journal = {Oxford Academia }, keywords = {SARs-CoV-2 covid ivermectin}, timestamp = {2022-04-24T19:59:36.000+0200}, title = {Meta-analysis of randomized trial of Ivermectin to treat SARs-CoV-2 infection}, url = {https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab358/6316214}, year = 2021 }